Incorporation of economic evidence in the Dutch guideline 'cardiovascular risk management'.
Tan
Siok Swan
SS
Erasmus Universiteit Rotterdam, Institute for Medical Technology Assessment, Rotterdam, the Netherlands. tan@bmg.eur.nl
Rutten
Frans F H
FF
Hakkaart-van Roijen
Leona
L
D000367:Age Factors; D000959:Antihypertensive Agents / Q000191:economics / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000191:economics* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004363:Drug Utilization; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D000960:Hypolipidemic Agents / Q000191:economics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D017410:Practice Guidelines as Topic; D019057:Quality-Adjusted Life Years; D012308:Risk Management / Q000191:economics*; D012737:Sex Factors
D000959:Antihypertensive Agents; D002317:Cardiovascular Agents; D000960:Hypolipidemic Agents